SGS's nomination for its "Successful development of a novel strain of Influenza A H3N2 for vaccine clinical trials" highlights its innovative H3N2 virus (A/Belgium/4217/2015), which can be used for human challenge testing in the company's dedicated clinical pharmacology unit in Antwerp, Belgium.
The European Innovations Awards program seeks to recognize outstanding examples of applied strategic innovation – partnerships, deployments, and collaborations that manifestly improve the clinical trial process. An expert panel of judges assesses entries looking for solutions that are innovative and needed in the industry.
Full details of the finalists can be found here.
For further information, please contact: